NEW ORLEANS, Oct. 23 /PRNewswire/ -- Tracey Technologies (Houston, Texas) announced today that it had submitted all physical object, human clinical, and software verification and validation testing data required under its agreement with VISX, Inc. , of Santa Clara, California, as of September 10, 2004.
“This represents the completion of a huge effort on our part to re- engineer our iTrace(TM) VFA to meet the compatibility standards outlined by VISX in our March 11, 2003 License Agreement,” stated Joe S. Wakil, MD, and Chairman of Tracey. “We are pleased to have VISX moving forward with software linking and FDA Equivalency filings as is called for under the agreement. It is anticipated that the software and engineering required will take a minimum of six months to complete. After completion of the engineering and software link, the parties will initiate the USA FDA approval process.”
Tracey Technologies, LLC is a developer and manufacturer of advance technology refractive diagnostic devices and systems. The company’s newest offering, the Tracey iTrace Visual Function Analyzer, combines ray-tracing aberrometry wavefront analysis with advanced corneal topography measurement and analysis. Tracey’s patented technology is viewed as the next generation of refractive diagnostics.
Tracey Technologies
CONTACT: Bill Roberts of CTC, +1-937-416-2742, for Tracey Technologies